Evidence map›Paper›PMID 36568272›Full record

ArticleCurrent research in pharmacology and drug discovery2022

4-Hydroxyisoleucine inhibits tumor growth by triggering endoplasmic reticulum stress and autophagy.

Peng Li, Yonghui Yang, Lu Qiu, Guangming Wan, Baomei Yuan, Yahong Wu, Yanfeng Gao, Guodong Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in pharmacology and drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Peng LiSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yonghui YangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Lu QiuSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Guangming WanThe First Affiliated Hospital of Zhengzhou University, China.
Baomei YuanSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yahong WuSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yanfeng GaoSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Guodong LiSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

4-Hydroxyisoleucine（4-HIL）is a non-protein amino acid that is able to reduce obesity and improve insulin sensitivity in mice, and recently emerged as a drug candidate against hypoglycemia. For the first time, we found that 4-HIL exhibits a potent anti-tumor activity in various cancer cell lines in

Indexed as

4-HydroxyisoleucineAutophagyEndoplasmic reticulum stressProtein synthesis

Identifiers

PMID36568272
PMCPMC9780060
OpenAlexW4295067298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.